Published in final edited form as:

J Gastrointest Surg. 2009 October ; 13(10): 1773–1780. doi:10.1007/s11605-009-0958-8.

An Analysis of Trends and Growth Factor Receptor Expression of GI Carcinoid Tumors

Kanika A. Bowen^{1,*}, Scott R. Silva¹, Jessica N. Johnson¹, Hung Q. Doan¹, Lindsey N. Jackson¹, Pat Gulhati¹, Suimin Qiu², Taylor S. Riall¹, and B. Mark Evers^{1,3}

¹ Department of Surgery, The University of Texas Medical Branch, Galveston, Texas

² Department of Pathology, The University of Texas Medical Branch, Galveston, Texas

³ Sealy Center for Cancer Cell Biology, The University of Texas Medical Branch, Galveston, Texas

Abstract

The purpose of our study was twofold: 1) to determine the incidence, patient and tumor characteristics, and outcome of patients with GI carcinoid tumors using the Surveillance, Epidemiology and End Results (SEER) database, and 2) to delineate the expression pattern of growth factor receptors (GFRs) in carcinoid tumors. The SEER database search provided information on patients diagnosed with carcinoid tumors from 1990–2002. Carcinoid tumor sections (n = 46) were stained for the GFRs: epidermal growth factor receptor (EGFR), insulin-like growth factor receptor (IGFR), vascular endothelial growth factor receptor (VEGFR), and HER-2/neu. Over the 12 year analysis period, 18,180 patients were identified with carcinoid tumors of the foregut, midgut, and hindgut; the incidence of carcinoid tumors increased ~2-fold during this time period. Of the patients with carcinoid tumors, there was a trend of increased expression of VEGF-R and IGF-R, particularly in the foregut and midgut carcinoids. Analysis of the SEER database confirms that the incidence of carcinoid tumors is increasing with an approximate doubling in the number of carcinoid cases from 1990–2002. Furthermore, an increase in VEGF-R and IGF-R expression suggests that GFR inhibitors may be effective adjuvant therapy for carcinoid cancer.

Keywords

VEGF-R; IGF-R; carcinoid tumors

INTRODUCTION

Carcinoid tumors are uncommon, slow growing neuroendocrine neoplasms arising from the enterochromaffin cells of the gut.¹ Although uncommon, carcinoids are increasing in incidence at a rate greater than other cancers.² Due to the indolent nature of carcinoid cancers, these tumors are usually not detected until after the development of metastases or intestinal fibrosis.³ Patients with metastatic disease may present with carcinoid syndrome, a set of symptoms including flushing, diarrhea, bronchospasm, and hypotension, or with manifestations of peritumoral and distant fibrosis.⁴ Common amine and peptide products secreted from carcinoids include serotonin, chromogranin A, and neurotensin.⁵

Send correspondence to: B. Mark Evers, M.D., Markey Cancer Center, University of Kentucky, 800 Rose Street, CC140, Lexington, KY 40536-0093, Telephone: (859) 323-6556, FAX: (859) 323-2074, mark.evers@uky.edu.

*Presented at the Society for Surgery of the Alimentary Tract on June 2, 2009, Chicago, IL

Currently, surgical resection is the only treatment with the possibility of achieving a cure and remains the mainstay of treatment for all patients with primary carcinoid tumors.⁶ Although there is ongoing research and clinical trials aimed at increasing survival of patients with metastatic disease, there has been no significant increase in survival in the past decade due, in part, to the lack of response to standard chemotherapeutic treatments.⁷ Somatostatin analogues have commonly been used for symptomatic relief of carcinoid syndrome after the development of hepatic metastasis.⁸ We have previously shown that administration of the somatostatin analogue octreotide significantly decreases hepatic metastasis using an *in vivo* mouse model, suggesting an antiproliferative effect of octreotide.⁹ Current combination chemotherapeutic regimens with streptozocin, 5-fluorouracil, and doxorubicin are commonly used in the treatment algorithms of highly proliferating carcinoid tumors.¹⁰

The lack of *in vitro* and *in vivo* model systems for carcinoid tumors has limited our understanding of the progression of this disease. We are fortunate to have established the novel carcinoid cell line BON, derived from a pancreatic carcinoid metastasis.¹¹ We have utilized the BON cell line to delineate signaling pathways regulating carcinoid cell growth and secretion.^{9, 11} BON cells express growth factor receptors (GFRs), including epidermal growth factor receptor (EGFR) and HER-2/neu, that may contribute to the development and sequelae of carcinoid tumors.^{12, 13} Recently, using the BON cell line, we developed a novel *in vivo* model of carcinoid syndrome which recapitulates many of the clinical sequelae noted in humans and determined that treatment with the VEGF inhibitor bevacizumab significantly inhibited tumor growth.¹⁴

Alterations in GFR expression have been linked to an increased risk of neoplastic transformation.¹⁵ Over-expression of HER-2/neu occurs in several cancers such as ovarian, stomach, breast, and aggressive forms of uterine cancer.^{16, 17} With ligand binding, EGFR stimulates intrinsic intracellular protein-tyrosine kinase activity which results in autophosphorylation of tyrosine residues. Downstream signaling proteins then initiate several signal transduction cascades, including the MAPK, phosphoinositide 3-kinase (PI3K), and JNK pathways, which are involved in important functions such as DNA synthesis and cell proliferation.^{18, 19} Insulin-like growth factor receptor (IGFR) is another receptor-tyrosine kinase that plays a critical role in cell survival and proliferation.²⁰ IGFR binding to its ligand activates the same pathways as EGFR to promote cell proliferation and suppress apoptosis.^{21, 22}

In the current study we analyzed carcinoid tumor incidence using The Surveillance, Epidemiology, and End Results (SEER) registry database of the National Cancer Institute and compared this to our institutional incidence. Furthermore, we analyzed the expression of various GFRs known to be involved in cancer development, including VEGFR, EGFR, IGFR, and HER-2/neu in a set of carcinoid tumors from our institutional tumor bank as well as from commercial tissue arrays.

MATERIAL AND METHODS

Materials

Rabbit monoclonal, anti-chromogranin, anti-synaptophysin, anti-VEGFR, anti IGFR, anti-EGFR, anti-PDGFR, and Her2/neu antibodies were purchased from Cell Signaling (Danvers, MA). Carcinoid tissue arrays were purchased from Biomax (Rockville, MD). Immunostaining was performed using a DAKO EnVision Kit (Carpinteria, CA).

Study design

The histopathology and clinical course of patients undergoing carcinoid resection from 1986–2006 at The University of Texas Medical Branch (UTMB) were retrospectively analyzed. UTMB Institutional Review Board approval was obtained for the collection of patient data, tissue acquisition, and subsequent use. A comprehensive search of the medical records was first performed using ICD-9 Common Procedure Terminology codes for “carcinoid,” “malignant carcinoid,” “carcinoid syndrome,” and “neuroendocrine tumor.” Histopathology reports were then obtained for all patients during the specified time period. Patients with a pathologically confirmed diagnosis of carcinoid (typical or atypical) were then entered into the UTMB Carcinoid Database. Demographic data (e.g., age, gender, race), TNM stage, lymph node status, presence of distant metastasis, and presence or absence of synchronous lesions was collected for all patients. For tissue analysis, paraffin-embedded blocks of resected carcinoid tissue were obtained from 20 UTMB patients with carcinoid tumors. Blocks were sectioned for immunohistochemistry.

SEER database

The National Cancer Institute’s SEER-9 program was used to collect national data on carcinoid incidence, patient age and gender distribution, tumor histology, TNM stage, lymph node status, and tumor size for the years 1990–2002. SEER data are compiled from population-based cancer data from nine cancer registries in geographically distinct areas of the US (five states: Connecticut, Hawaii, Iowa, New Mexico, and Utah; four cities: Atlanta, Detroit, San Francisco, and Seattle).²³ Population data for additional statistical analysis was obtained from the 2000 US Census Bureau (available at: www.census.gov).

Immunohistochemistry

Paraffin-embedded carcinoid blocks were sectioned (5 μ m) and deparaffinized in xylene and rehydrated in descending ethanol series. Immunostaining was performed using a DAKO EnVision Kit (Dako Corp) as we have described previously.²⁴ Briefly, sections were incubated overnight at 4°C with monoclonal antibodies diluted 1:100 in 0.05 M Tris-HCL with 1% BSA against anti-chromogranin, anti-synaptophysin, anti-EGFR, anti-VEGFR, anti-IGFR, and anti-HER-2/neu antibodies (Cell Signaling). After three washes with TBST, sections were incubated for 30 min with secondary antibody labeled with peroxidase, then washed three times with TBST. Lastly, peroxidase substrate diaminobenzidinetetrahydrochloride was added for staining. All sections were counterstained with hematoxylin and observed by light microscopy. All specimens were reviewed by a pathologist in a blinded fashion.

Statistical analysis

Differences in GFR expression were assessed using Pearson chi-square test. Comparison of UTMB and SEER data was tested using the Pearson chi-square test for GFRs, gender, race, and tumor stage and, using the median test for age, presence of positive lymph nodes, and synchronous lesions. Association between carcinoid location and data set (UTMB or SEER), controlling for gender or race, was assessed using the Cochran-Mantel-Haenszel test. Associations between carcinoid tumors and GFRs were assessed using the Pearson chi-square test for gender, tumor stage, presence of positive lymph nodes, presence of synchronous lesions, and using the median test for age and tumor size. All statistical computations were carried out using SAS statistical software (Release 9.1; SAS Institute).

RESULTS

UTMB patient demographics

Between January 1986 and December 2006, 45 patients had resections performed for GI carcinoid tumors at UTMB. There was a total of 21 women (47.7%) and 23 men (52.3%), with a mean age of 59 years (range 34–77 years). The average age was 59.3 years with a standard deviation of 11.7 years. Caucasians represented 75% of all patients, followed by African-Americans (13.6%), and Hispanics (11.4%). The most common site of occurrence was the foregut (45.4%), followed by midgut (39.2%) and hindgut (9.1%). When carcinoid tumors were further divided by organ system the small intestine was the most common site (36.4%), followed by the respiratory tract (31.8%), colorectal/anal (9.1%), stomach (6.8%), pancreas (6.8%), and appendix (2.3%). 6.8% of patients with disseminated disease at the time of presentation had an unknown primary tumor. Lymph node metastases were present in 29 patients (65.9%), 9 patients (20.5%) had node negative disease, and 6 patients (13.6%) had unknown nodal status. The majority of patients (54.5%) presented to UTMB with disseminated distant disease, and 25.5% of patients had localized or regional disease. Tumor stage was unknown in 4.5% of patients.

Comparison of UTMB patients with the SEER database

Demographics for patients with carcinoid tumors diagnosed at UTMB and those recorded in the SEER database are presented in Table 1. A search of the SEER database identified 18,180 patients with carcinoid tumors during the study period. The incidence of carcinoid tumors in the foregut, midgut, and hindgut increased ~2-fold during this time period. The two populations had a similar ratio of male and female patients. Median age was slightly higher in SEER patients (62 versus 59; $p = .09$). Racial distribution was also noted to be similar between the two populations. UTMB had a slightly higher percentage of African-American and Hispanic patients compared to the SEER database. The majority of SEER patients presented with localized disease (48%); 23% of patients presented with distant disease. In contrast, ~54.5% of UTMB patients presented with distant disease.

Comparison of GFR expression in carcinoid tumors

Specific immunohistochemistry staining for carcinoid tissues using chromogranin A and synaptophysin verified that the tissue sections were carcinoid tumors. Associations between outcome measures, tumor location (foregut, midgut or hindgut), patient age and sex were assessed using the multiple logistic regression model. Hindgut carcinoids were excluded from the multiple logistic regression model due to very small sample size ($n = 4$).

Of 46 samples stained for immunohistochemistry, all stained positive for synaptophysin. Association between carcinoid location and gender are summarized for UTMB or commercial arrays in Table 2. A significant association was not observed between gender and carcinoid location adjusting for UTMB versus tissue array ($p=0.64$). This indicates that the ratio of males to females from each carcinoid location was similar. However a significant association was observed between UTMB or tissue array and location adjusting for gender ($p=0.005$). This suggests that the number of samples from each carcinoid location were significantly different between UTMB and array tissues when adjusted for gender. The majority of tissue arrays were from the foregut, whereas tissues from UTMB patients were similarly distributed between foregut and midgut tumors.

Mean patient age for each carcinoid location with number of samples and standard deviation was analyzed. There were no significant differences in patient age compared with carcinoid location ($p=0.38$), however, there was a statistically significant age difference between foregut

and midgut carcinoid tumors among males at UTMB. The mean ages were 48 and 68 with a standard deviation of 12 and 9 years for foregut and midgut tumors, respectively ($p < 0.05$).

Representative tissue staining patterns from selected UTMB patients are shown in Figure 1. Similar sections of carcinoid tumors with areas of normal tissue were chosen to illustrate changes in the expression of various proteins. These samples were representative of all specimens analyzed. Expression of CgA was observed in the selected foregut, midgut, and hindgut tissues. Strong EGFR expression was observed in lung carcinoids whereas weak expression was observed in small bowel sections. Lung, gastric, and small bowel carcinoids all stained strongly positive for VEGFR expression. Weak VEGFR expression was also noted in hindgut carcinoids. Strong IGFR expression was found in lung, gastric, and small bowel carcinoids, whereas weak expression was observed in hindgut carcinoids. HER-2/neu was expressed in all of the tissues except for hindgut carcinoids.

Comparison of receptor staining between UTMB patient samples and commercial tissue arrays is summarized in Table 3. Ninety percent of UTMB samples (18/20) stained positive for IGFR. On the other hand, 88% of array samples (22/25) were negative for IGFR expression. Twenty-nine percent of array samples (7/24) were HER-2/neu positive while only 15% of UTMB samples (3/20) stained positive for HER-2/neu. When all carcinoid tissues were categorized based on tissue location and receptor staining, VEGFR expression was fairly evenly distributed among foregut and midgut carcinoids and all hindgut carcinoids exhibited positive expression (Table 4). IGFR expression was greater in midgut carcinoids compared to foregut carcinoids. Gender did not significantly influence the outcome of GFR expression (Table 5). Although not statistically significant ($p = 0.10$), males were ~8 times less likely to have positive staining for EGFR. Patients less than 50 years of age were ~9 times ($p = 0.07$) more likely to have positive staining for VEGFR than patients between 50 and 59 (Table 6). The odds ratio of exhibiting positive VEGFR staining in patients 60 years or older was almost identical to those between 50 and 59. Patients under age 50 years of age were ~24 times more likely ($p = 0.048$) to have positive staining for IGFR than patients between the ages of 50 and 59. The odds ratio of patients 60 years or older demonstrating IGFR expression was almost identical to those between the ages of 50 and 59.

DISCUSSION

In 1907, Siegfried Obendorfer, a German pathologist, coined the term *karzinoide*, to describe a benign tumor resembling a carcinoma microscopically.²⁵ In 1948, serotonin was identified from the Kulchitsky cell, and later hypothesized to be the hormone responsible for carcinoid syndrome.²⁶ Since this time studies have attempted to determine targets for the treatment of carcinoid tumors. Recently, there has been growing interest in the use of GFR inhibitors in the treatment of carcinoid tumors. Endostatin, sunitinib, sorafenib, and bevacizumab are drugs that are under investigation and have shown promise.^{27–29} Although carcinoid tumors are mostly slow growing and indolent in nature, current chemotherapeutic options have not altered survival. Somatostatin analogues attenuate the symptoms of carcinoid syndrome but their effects on tumor growth are controversial. Currently, platinum-based chemotherapy is not useful in these patients and traditional single agents are only minimally effective in a small number of patients.^{30, 31}

Increased expression of GFRs has previously been demonstrated in neuroendocrine tumors and has been implicated as a possible mechanism for tumor development and progression. Carcinoid tumors are highly vascular in nature with many of these tumors exhibiting a marked desmoplastic reaction. Expression of VEGF has been demonstrated in both gastrointestinal and pulmonary carcinoids.^{32, 33} Recently, over-expression of VEGF was found to promote the growth of human neuroendocrine tumors through the up-regulation of angiogenesis;

bevacizumab significantly reduced tumor angiogenesis and impaired tumor growth *in vivo*.³⁴ Similarly, our group found that treatment with bevacizumab significantly inhibited tumor growth using a novel *in vivo* metastasis model.¹⁴ Increased VEGF expression appears to correlate with metastases and decreased progression-free survival.³⁵ In our current study, we demonstrated that carcinoid tumors from patients under 50 years of age were more likely to express VEGFR. These findings are intriguing and suggest that targeting VEGFR may represent a treatment option in a subset of patients with carcinoid tumors.

IGFR is implicated as an important component of growth factor signaling in neuroendocrine tumors.³⁶ We found increased IGFR expression in UTMB patient tissues when compared to the commercial array tissues, which may be attributed to the increased number of midgut carcinoids in the UTMB patient population. Patients under 50 years of age were also more likely to have increased expression of IGFR. Exogenous IGF has been shown to activate mTOR and increase cellular proliferation in carcinoid cells.³⁷ Due to the importance of IGFR signaling in carcinomas it has become another possible target for kinase inhibitors. Our findings suggest that IGFR is important in carcinoid tumors, specifically in younger patients. In the future this finding may lead to the investigation of patient specific treatment therapies based on patient age. Although EGFR expression has been identified in carcinoid tumors of the gastrointestinal tract, we did not observe a significant trend in EGFR expression in our current study. Previously, EGFR and p-EGFR were found to be more highly expressed in small-bowel carcinoid tumors compared with islet-cell tumors, and p-EGFR expression was associated with decreased survival among patients with pancreatic endocrine tumors.³⁸ Even though previous studies have shown increased expression of PDGFR in carcinoid tumors, we did not detect PDGFR expression in carcinoid tumors from our patient population. In a phase-II study of imatinib, which is specific for the tyrosine kinase domain in PDGFR, there was no significant regression of carcinoid disease, but a significant number of patients with progressive disease did achieve disease stabilization.³⁹ This suggests that although imatinib may not be a future first-line agent in the treatment of carcinoid tumors it may play a role in palliative treatment.

Slow growing carcinoids are often indolent in nature and like other cancers with a similar course they are often discovered in advanced stages of the disease. Currently, complete operative resection is the only option for cure. Recent clinical trials evaluating the effectiveness of GFR inhibition show promise in disease stabilization but more research in combination drug therapy is forthcoming. Our study highlights the importance of GFR signaling in carcinoid tumors, specifically VEGFR and IGFR, and provides evidence to support current investigations into the inhibition of these GFRs as a novel treatment strategy for carcinoids. Evaluation of the SEER database demonstrated a two-fold increase in the number of carcinoids over the last decade. During that time the most common site of occurrence was in the foregut followed by midgut and hindgut locations. When divided by organ system, the small intestine was the most common site of occurrence. Although there has not been a significant change in survival, new information about the occurrence of GFRs in carcinoid tumors will provide novel treatment options in the future.

Acknowledgments

This work was supported by grants RO1 CA104748, RO1 DK48498, PO1DK35608, RO1 CA125454 (to BPZ) and T32DK07639 from the National Institutes of Health. KB is a recipient of a Jeane B. Kempner Scholar Award.

The authors thank Karen Martin for manuscript preparation, and Tatsuo Uchida for statistical analysis.

References

1. Kulke MH. Clinical presentation and management of carcinoid tumors. *Hematol Oncol Clin North Am* 2007;21:433–455. vii–viii. [PubMed: 17548033]

2. Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. *Cancer* 2003;97:934–959. [PubMed: 12569593]
3. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A, Evans DB. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. *J Clin Oncol* 2008;26:3063–3072. [PubMed: 18565894]
4. Gustafsson BI, Kidd M, Chan A, Malfertheiner MV, Modlin IM. Bronchopulmonary neuroendocrine tumors. *Cancer* 2008;113:5–21. [PubMed: 18473355]
5. Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker RV, Caplin M, Delle Fave G, Kaltsas GA, Krenning EP, Moss SF, Nilsson O, Rindi G, Salazar R, Ruszniewski P, Sundin A. Gastroenteropancreatic neuroendocrine tumours. *Lancet Oncol* 2008;9:61–72. [PubMed: 18177818]
6. Pinchot SN, Pitt SC, Sippel RS, Kunnimalaiyaan M, Chen H. Novel targets for the treatment and palliation of gastrointestinal neuroendocrine tumors. *Curr Opin Investig Drugs* 2008;9:576–582.
7. Modlin IM, Moss SF, Chung DC, Jensen RT, Snyderwine E. Priorities for improving the management of gastroenteropancreatic neuroendocrine tumors. *J Natl Cancer Inst* 2008;100:1282–1289. [PubMed: 18780869]
8. Srirajaskanthan R, Toumpanakis C, Meyer T, Caplin ME. Future therapies for management of metastatic gastroenteropancreatic neuroendocrine tumours. *Aliment Pharmacol Ther*. 2009 in press.
9. Evers BM, Townsend CM Jr, Upp JR, Allen E, Hurlbut SC, Kim SW, Rajaraman S, Singh P, Reubi JC, Thompson JC. Establishment and characterization of a human carcinoid in nude mice and effect of various agents on tumor growth. *Gastroenterology* 1991;101:303–311. [PubMed: 1712329]
10. Pinchot SN, Holen K, Sippel RS, Chen H. Carcinoid tumors. *Oncologist* 2008;13:1255–1269. [PubMed: 19091780]
11. Evers BM, Ishizuka J, Townsend CM Jr, Thompson JC. The human carcinoid cell line, BON. A model system for the study of carcinoid tumors. *Ann N Y Acad Sci* 1994;733:393–406. [PubMed: 7978888]
12. Stilling GA, Zhang H, Ruebel KH, Leontovich AA, Jin L, Tanizaki Y, Zhang S, Erickson LA, Hobday T, Lloyd RV. Characterization of the functional and growth properties of cell lines established from ileal and rectal carcinoid tumors. *Endocr Pathol* 2007;18:223–232. [PubMed: 18247165]
13. Gugger M, Burckhardt E, Kappeler A, Hirsiger H, Laissue JA, Mazzucchelli L. Quantitative expansion of structural genomic alterations in the spectrum of neuroendocrine lung carcinomas. *J Pathol* 2002;196:408–415. [PubMed: 11920736]
14. Jackson LN, Chen LA, Larson SD, Silva SR, Rychahou PG, Boor PJ, Li J, Defreitas G, Stafford WL, Townsend CM Jr, Evers BM. Development and Characterization of a Novel In vivo Model of Carcinoid Syndrome. *Clin Cancer Res* 2009;15:2747–2755. [PubMed: 19336516]
15. Zhang H, Berezov A, Wang Q, Zhang G, Drebin J, Murali R, Greene MI. ErbB receptors: from oncogenes to targeted cancer therapies. *J Clin Invest* 2007;117:2051–2058. [PubMed: 17671639]
16. Santin AD, Bellone S, Roman JJ, McKenney JK, Pecorelli S. Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neu. *Int J Gynaecol Obstet* 2008;102:128–131. [PubMed: 18555254]
17. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. *Nat Rev Mol Cell Biol* 2001;2:127–137. [PubMed: 11252954]
18. Oda K, Matsuoka Y, Funahashi A, Kitano H. A comprehensive pathway map of epidermal growth factor receptor signaling. *Mol Syst Biol* 2005;1:0010. [PubMed: 16729045]
19. Sharma PS, Sharma R, Tyagi T. Receptor tyrosine kinase inhibitors as potent weapons in war against cancers. *Curr Pharm Des* 2009;15:758–776. [PubMed: 19275641]
20. Galvan V, Logvinova A, Sperandio S, Ichijo H, Bredesen DE. Type 1 insulin-like growth factor receptor (IGF-IR) signaling inhibits apoptosis signal-regulating kinase 1 (ASK1). *J Biol Chem* 2003;278:13325–13332. [PubMed: 12556535]
21. Warshamana-Greene GS, Litz J, Buchdunger E, Garcia-Echeverria C, Hofmann F, Krystal GW. The insulin-like growth factor-I receptor kinase inhibitor, NVP-ADW742, sensitizes small cell lung cancer cell lines to the effects of chemotherapy. *Clin Cancer Res* 2005;11:1563–1571. [PubMed: 15746061]
22. Jones HE, Goddard L, Gee JM, Hiscox S, Rubini M, Barrow D, Knowlden JM, Williams S, Wakeling AE, Nicholson RI. Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib

- (ZD1839; Iressa) in human breast and prostate cancer cells. *Endocr Relat Cancer* 2004;11:793–814. [PubMed: 15613453]
23. Program, S. SEER program public-use data (1973–2003). [Accessed: August 2007]. Available at: <http://seer.cancer.gov>
 24. Rychahou PG, Jackson LN, Silva SR, Rajaraman S, Evers BM. Targeted molecular therapy of the PI3K pathway: therapeutic significance of PI3K subunit targeting in colorectal carcinoma. *Ann Surg* 2006;243:833–842. discussion 843–834. [PubMed: 16772787]
 25. Obendorfer S. Karzinoide tumoren des dunndarms. *Frankf Zschr Pathol* 1907;1:426–430.
 26. Erspamer V, Asero B. Identification of enteramine, the specific hormone of the enterochromaffin cell system, as 5-hydroxytryptamine. *Nature* 1952;169:800–801. [PubMed: 14941051]
 27. Kulke MH, Lenz HJ, Meropol NJ, Posey J, Ryan DP, Picus J, Bergsland E, Stuart K, Tye L, Huang X, Li JZ, Baum CM, Fuchs CS. Activity of sunitinib in patients with advanced neuroendocrine tumors. *J Clin Oncol* 2008;26:3403–3410. [PubMed: 18612155]
 28. Zitzmann K, De Toni EN, Brand S, Goke B, Meinecke J, Spottl G, Meyer HH, Auernhammer CJ. The novel mTOR inhibitor RAD001 (everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells. *Neuroendocrinology* 2007;85:54–60. [PubMed: 17310129]
 29. Yao JC, Hoff PM. Molecular targeted therapy for neuroendocrine tumors. *Hematol Oncol Clin North Am* 2007;21:575–581. x. [PubMed: 17548041]
 30. Kouvaraki MA, Ajani JA, Hoff P, Wolff R, Evans DB, Lozano R, Yao JC. Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. *J Clin Oncol* 2004;22:4762–4771. [PubMed: 15570077]
 31. Sun W, Lipsitz S, Catalano P, Mailliard JA, Haller DG. Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281. *J Clin Oncol* 2005;23:4897–4904. [PubMed: 16051944]
 32. Terris B, Scoazec JY, Rubbia L, Bregeaud L, Pepper MS, Ruzsiewicz P, Belghiti J, Flejou J, Degott C. Expression of vascular endothelial growth factor in digestive neuroendocrine tumours. *Histopathology* 1998;32:133–138. [PubMed: 9543669]
 33. Ambs S, Bennett WP, Merriam WG, Ogunfusika MO, Oser SM, Khan MA, Jones RT, Harris CC. Vascular endothelial growth factor and nitric oxide synthase expression in human lung cancer and the relation to p53. *Br J Cancer* 1998;78:233–239. [PubMed: 9683299]
 34. Zhang J, Jia Z, Li Q, Wang L, Rashid A, Zhu Z, Evans DB, Vauthey JN, Xie K, Yao JC. Elevated expression of vascular endothelial growth factor correlates with increased angiogenesis and decreased progression-free survival among patients with low-grade neuroendocrine tumors. *Cancer* 2007;109:1478–1486. [PubMed: 17340592]
 35. Phan, ATWL.; Xie, K., et al. Association of VEGF expression with poor prognosis among patients with low-grade neuroendocrine carcinoma. Annual Meeting of American Society of Clinical Oncology; Atlanta, GA: American Society of Clinical Oncology; 2006.
 36. Nilsson O, Wangberg B, Theodorsson E, Skottner A, Ahlman H. Presence of IGF-I in human midgut carcinoid tumours--an autocrine regulator of carcinoid tumour growth? *Int J Cancer* 1992;51:195–203. [PubMed: 1314781]
 37. von Wichert G, Jehle PM, Hoeflich A, Koschnick S, Dralle H, Wolf E, Wiedenmann B, Boehm BO, Adler G, Seufferlein T. Insulin-like growth factor-I is an autocrine regulator of chromogranin A secretion and growth in human neuroendocrine tumor cells. *Cancer Res* 2000;60:4573–4581. [PubMed: 10969809]
 38. Papouchado B, Erickson LA, Rohlinger AL, Hobday TJ, Erlichman C, Ames MM, Lloyd RV. Epidermal growth factor receptor and activated epidermal growth factor receptor expression in gastrointestinal carcinoids and pancreatic endocrine carcinomas. *Mod Pathol* 2005;18:1329–1335. [PubMed: 15920550]
 39. Carr KYJ, Rashid A, et al. A phase II trial of imatinib in patients with advanced carcinoid tumor. *Journal of Clinical Oncology* 2004;22:4124.

Figure 1. Expression of growth factor receptors in carcinoid cancer tissues

Immunohistochemical analysis of chromogranin A (CgA), epidermal growth factor receptor (EGFR), vascular endothelial growth factor receptor (VEGFR), insulin-like growth factor receptor (IGFR), and HER-2/neu in representative carcinoid cancer tissues derived from the foregut, midgut and hindgut (4X magnification with 10x inlay).

Table 1

Comparison of University of Texas Medical Branch Patient Demographics with Surveillance, Epidemiology, and End Results Database.

	SEER 1990–2002 (N=18,180)	UTMB 1990–2006 (N=44)	p-Value
Age; Median	61.9+/-14.4	59.3+/-11.7	0.09
Gender			0.54
Male	47.7%	52.3%	
Female	52.3%	47.7%	
Race			0.14
White	74.3%	75.0%	
Black	12.6%	13.6%	
Hispanic	5.9%	11.4%	
Other	7.6%	0.0%	
Site of Carcinoid			<0.0001
Small intestine	20.8%	36.4%	
Colorectal/anal	28.0%	9.1%	
Appendix	3.3%	2.3%	
Stomach	6.3%	6.8%	
Pancreas	4.4%	6.8%	
Liver/GB/bile ducts/ampulla	1.7%	0.0%	
Other digestive	0.9%	0.0%	
Lung/Respiratory	34.0%	31.8%	
Esophagus	0.2%	0.0%	
Retroperitoneal	0.4%	0.0%	
Unknown	0.0%	6.8%	
Nodal Status			<0.0001
Negative	49.4%	20.5%	
Positive	15.8%	65.9%	
Unknown	34.8%	13.6%	
Stage			<0.0001
Localized	48.0%	20.5%	
Regional	21.0%	20.5%	
Distant	23.4%	54.5%	
Unknown	7.6%	4.5%	
Survival (Overall)			0.52
1-year	77.4%	80.9%	
3-year	65.3%	77.4%	
5-year	57.9%	61.2%	
median	93 months	138 months	

Table 2

Comparison of Gender and Frequency of Carcinoid Tumor Location for University of Texas Medical Branch and Tissue Array Patients

	Foregut N (%)	Midgut N (%)	Hindgut N (%)	Total N
Female				
UTMB	5 (42%)	5 (42%)	2 (16%)	12
Array	7 (78%)	1 (11%)	1 (11%)	9
Male				
UTMB	3 (38%)	4 (50%)	1 (12%)	8
Array	16 (94%)	1 (6%)	0 (0%)	17

Table 3

University of Texas Medical Branch vs. Tissue Array Growth Factor Receptor Staining

	CgA	EGF-R	VEGF-R	IGF-R	Her2/neu
	N (%)	N (%)	N (%)	N (%)	N (%)
UTMB	20 (100%)	3 (15%)	12 (60%)	18 (90%)	3 (15%)
Array	21 (84%)	3 (13%)	10 (42%)	3 (12%)	7 (29%)

Table 4
Comparison of Gender and Frequency of Carcinoid Tumor Growth Factor Receptor Staining

Gender	CgA N (%)	EGF-R N (%)	VEGF-R N (%)	IGF-R N (%)	Her2/neu N (%)
Female	20 (95%)	5 (25%)	12 (60%)	11 (52%)	6 (30%)
Male	21 (88%)	1 (4%)	10 (42%)	10 (42%)	7 (17%)

Table 5
Comparison of Carcinoid Tumor Location and Frequency for Growth Factor Receptor Staining

	CgA N (%)	EGF-R N (%)	VEGF-R N (%)	IGF-R N (%)	Her2/neu N (%)
Foregut	26 (87%)	4 (13%)	14 (47%)	9 (30%)	8 (27%)
Midgut	11 (100%)	2 (20%)	4 (40%)	9 (82%)	2 (20%)
Hindgut	4 (100%)	0 (0%)	4 (100%)	3 (75%)	0 (0%)

Table 6

Comparison of Age and Frequency for Growth Factor Receptor Staining

Age Group	CgA N (%)	EGF-R N (%)	VEGF-R N (%)	IGF-R N (%)	Her2/neu N (%)
24-49	10 (100%)	0 (0%)	8 (89%)	8 (80%)	3 (33%)
50-59	15 (88%)	5 (29%)	7 (41%)	6 (35%)	3 (17%)
60-79	16 (89%)	1 (6%)	7 (39%)	7 (39%)	4 (22%)